Abstract: The invention provides a pharmaceutical composition of hyaluronic acid comprising repeating units of a disaccharide comprising glucuronic acid and N-acetylglucosamine, wherein a portion of the N-acetyl groups of the N-acetylglucosamine have been independently replaced with a group of the formula —N—C(O)—(C2-C4)-alkyl for treating hyperuicemia and gouty arthritis. Studies show that this composition is promising as an anti-gout therapeutic agent, which combines both anti-inflammatory actions as well as anti uracemic effects.

Abstract: A composition and method for promoting wound healing that includes hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted.

Abstract: The invention provides a pharmaceutical composition of hyaluronic acid comprising repeating units of a disaccharide comprising glucuronic acid and N-acetylglucosamine, wherein a portion of the N-acetyl groups of the N-acetylglucosamine have been independently replaced with a group of the formula —N—C(O)—(C2-C4)-alkyl for treating hyperuicemia and gouty arthritis. Studies show that this composition is promising as an anti-gout therapeutic agent, which combines both anti-inflammatory actions as well as anti uracemic effects.

Abstract: The present disclosure relates to hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted, and methods and uses thereof.

Abstract: The present disclosure relates to hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted, and methods and uses thereof.

Abstract: The present disclosure relates to hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted, and methods and uses thereof.

Abstract: The present disclosure relates to hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted, and methods and uses thereof.

Abstract: A method of treating a mammal for a purpose selected from the group consisting of (a) increasing bone mineral density (BMD), (b) treating low BMD, (c) preventing and treatment of low impact fractures, (d) treatment of high impact fractures; (e) treating osteoporosis; (f) modulating a growth factor that influences bone metabolism; and (g) improving bone micro-architecture or connectivity of bone; the method comprising administering to the mammal an effective amount of a N-acylated-2-glucosamine derivative of the general formula (I): wherein R is an alkyl radical of the general formula CnH2n+1 and n is selected from 2-12; or pharmaceutically-acceptable salts, esters and glucosides thereof; or pharmaceutically-acceptable compositions thereof.

Abstract: A method of treating a mammal for a purpose selected from the group consisting of (a) increasing bone mineral density (BMD), (b) treating low BMD, (c) preventing and treatment of low impact fractures, (d)treatment of high impact fractures; (e) treating osteoporosis; (f) modulating a growth factor that influences bone metabolism; and (g) improving bone micro-architecture or connectivity of bone; the method comprising administering to the mammal an effective amount of a N-acylated-2-glucosamine derivative of the general formula (I):- wherein R is an alkyl radical of the general formula CnH2n+1 and n is selected from 2-12; or pharmaceutically-acceptable salts, esters and glucosides thereof; or pharmaceutically-acceptable compositions thereof.

Abstract: A pharmaceutical composition comprising a prostaglandin such as misoprostol and TGF-B in amounts sufficient to stimulate production of chondrocyte matrix is disclosed which exhibit therapeutic synergy.